An randomised, double-blind, placebo-controlled, parallel group study to assess the efficacy and safety of dutasteride 0.5mg once daily for 6 months in the treatment of male subjects with androgenetic alopecia (Norwood-Hamilton Classification Type IIIv, IV and V).
Latest Information Update: 05 Sep 2023
At a glance
- Drugs Dutasteride (Primary)
- Indications Alopecia
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 03 Jun 2010 Results published in the Journal of the American Academy of Dermatology.
- 05 May 2009 Actual number of patients added as 153 as reported by ClinicalTrials.gov.
- 15 Oct 2008 Actual start date changed from Dec 2006 to Jan 2007 as reported by ClinicalTrials.gov.